[HTML][HTML] Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
…, A Lombardi, RV Shah, LJ Hirsch… - … England Journal of …, 1995 - Mass Medical Soc
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in
Postmenopausal Osteoporosis | NEJM Skip to main content NEJM Group Follow Us Facebook …
Postmenopausal Osteoporosis | NEJM Skip to main content NEJM Group Follow Us Facebook …
Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS)
…, LI Vailas, P Alaupovic, LJ Hirsch… - Annals of Internal …, 1993 - acpjournals.org
Objective: To assess the effects of lipid-lowering therapy with lovastatin on coronary
angiographic findings in patients with coronary artery disease and to compare the findings with …
angiographic findings in patients with coronary artery disease and to compare the findings with …
[HTML][HTML] Esophagitis associated with the use of alendronate
PC De Groen, DF Lubbe, LJ Hirsch… - … England Journal of …, 1996 - Mass Medical Soc
Background Alendronate, an aminobisphosphonate and a selective inhibitor of osteoclast-mediated
bone resorption, is used to treat osteoporosis in postmenopausal women and …
bone resorption, is used to treat osteoporosis in postmenopausal women and …
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
KS Polonsky, BD Given, LJ Hirsch, H Tillil… - … England Journal of …, 1988 - Mass Medical Soc
To determine whether non-insulin-dependent diabetes is associated with specific alterations
in the pattern of insulin secretion, we studied 16 patients with untreated diabetes and 14 …
in the pattern of insulin secretion, we studied 16 patients with untreated diabetes and 14 …
Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations
…, CH Arce, KJ Byron, LJ Hirsch - Current medical research …, 2010 - Taylor & Francis
Objective: During subcutaneous insulin therapy, inadvertent intramuscular (IM) injections may
increase pain and/or adversely affect glucose control. The most appropriate needle length …
increase pain and/or adversely affect glucose control. The most appropriate needle length …
[HTML][HTML] New insulin delivery recommendations
…, G Kreugel, G Grassi, S Halimi, D Hicks, LJ Hirsch… - Mayo Clinic …, 2016 - Elsevier
Many primary care professionals manage injection or infusion therapies in patients with
diabetes. Few published guidelines have been available to help such professionals and their …
diabetes. Few published guidelines have been available to help such professionals and their …
Prevention of nonvertebral fractures by alendronate: a meta-analysis
…, S Adami, ST Harris, AC Santora, LJ Hirsch… - JaMa, 1997 - jamanetwork.com
Objective. —To evaluate the effect of treatment with alendronate sodium, a potent
aminobisphosphonate, on the incidence of nonvertebral fractures in postmenopausal women with …
aminobisphosphonate, on the incidence of nonvertebral fractures in postmenopausal women with …
Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control
…, L Kaltheuner, L Heinemann, T Heise, L Hirsch - Diabetes …, 2016 - Am Diabetes Assoc
OBJECTIVE Lipohypertrophy (LHT) is common in insulin-treated patients but its exact impact
on insulin absorption and action is unclear. RESEARCH DESIGN AND METHODS In this …
on insulin absorption and action is unclear. RESEARCH DESIGN AND METHODS In this …
[HTML][HTML] Worldwide injection technique questionnaire study: injecting complications and the role of the professional
AH Frid, LJ Hirsch, AR Menchior, DR Morel… - Mayo Clinic …, 2016 - Elsevier
From February 1, 2014, through June 30, 2015, 13,289 insulin-injecting patients from 423
centers in 42 countries participated in one of the largest surveys ever performed in diabetes. …
centers in 42 countries participated in one of the largest surveys ever performed in diabetes. …
Comparative glycemic control, safety and patient ratings for a new 4 mm× 32G insulin pen needle in adults with diabetes
LJ Hirsch, MA Gibney, J Albanese, S Qu… - … medical research and …, 2010 - Taylor & Francis
Objective: Pen needles (PN) for subcutaneous insulin therapy have become smaller; 5 mm
PNs are now the shortest in use. We evaluated the safety, efficacy and patient ratings of a …
PNs are now the shortest in use. We evaluated the safety, efficacy and patient ratings of a …